Megabol 200mg/ml 10ml – Medical Pharma Steroids Online USA

C22H32O3 = 344.5.
CAS — 57-85-2.
ATC — G03BA03.
ATC Vet — QG03BA03.

USP 31 (Testosterone Propionate). White or creamy-white, odourless, crystals or crystalline powder. Insoluble in water; freely soluble in alcohol, in dioxan, in ether, and in other organic solvents; soluble in vegetable oils. Protect from light.

Trenbolone Acetate; Acetato de trenbolona; RU-1697; Trenbolone, Acétate de; Trenboloni Acetas; Trienbolone Acetate. 17β-Hydroxyestra-4,9,11-trien-3-one acetate.
C20H24O3 = 312.4.
CAS — 10161-33-8 (trenbolone); 10161-34-9 (trenbolone acetate).
Pharmacopoeias.
USP 31(Trenbolone Acetate). Solution oily transparent color from light yellow to yellow, with characteristic odor.

Megabol contains : 200mg

75 mg / ml Trenbolone Acetate.
50 mg / ml Methandrostenolone.
75 mg / ml Testosterone Propionate.

Pharmacologic Category: Androgen.

Dosing: Adult 200mg injected IM every 3-5 days for duration of 4-8 weeks.
Dosing: Geriatric.
Refer to adult dosing.
Dosing: Pediatric: Has not been tested in pediatric population.
Dosing: Renal Impairment: No dosage adjustment provided in manufacturer’s labeling; use with caution.
Dosing: Hepatic Impairment: No dosage adjustment provided in manufacturer’s labeling; use with caution.

Use:

Labeled Indications

Trenbolone also has the ability to greatly increase red blood cell count and IGF-1 output. The increased red blood cell count is important as red blood cells are responsible for carrying oxygen to and through the blood.

Methandienone has anabolic and some androgenic properties. It has little progestogenic activity.

Testosterone Propionate is a pure testosterone hormone. Although synthetic it is a perfect replica of the primary naturally produced male androgen testosterone. By design, the hormone is attached to the Propionate (propionic acid) ester, a small/short ester that enables the hormone’s release time to be controlled. Without an ester, the hormone would disperse and dissipate rapidly post administration.

Androgens are primarily indicated in males as replacement therapy when congenital or acquired endogenous androgen absence or deficiency is associated with primary or secondary hypogonadism. Primary hypogonadism includes conditions such as: testicular failure due to cryptorchidism, bilateral torsion, orchitis, or vanishing testis syndrome; orchidectomy, Klinefelter’s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. Hypogonadotropic hypogonadism (secondary hypogonadism) conditions include idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury as a result of tumors, trauma, or radiation and are the most common forms of hypogonadism seen in older adults.

Storage/Stability

Store at room temperature. Protect from light.

Contraindications

Hypersensitivity to any component of the formulation; males with carcinoma of the breast or known or suspected carcinoma of the prostate; women who are breast-feeding, pregnant, or who may become pregnant.

Pregnancy risk factor X

Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

Pregnancy considerations

Megabol may cause adverse effects, including masculinization of the female fetus, if used during pregnancy. Females who are or may become pregnant should also avoid skin-to-skin contact to areas where testosterone has been applied on another person.

Lactation

Contraindicated

Breast feeding considerations

High levels of endogenous maternal testosterone, such as those caused by certain ovarian cysts, suppress milk production. Maternal serum testosterone levels generally fall following pregnancy and return to normal once breast-feeding is stopped. The amount of testosterone present in breast milk or the effect to the nursing infant following maternal supplementation is not known. Some products are contraindicated while breast-feeding. Females who are nursing should avoid skin-to-skin contact to areas where testosterone has been applied topically on another person.

Adverse reactions

This compound is highly hepatotoxic.

Cardiovascular: Hypertension (≥3%), increased blood pressure (1%), decreased blood pressure, deep vein thrombosis, edema, vasodilatation.

Central nervous system: Headache (1% to ≥3%), fatigue (2%), irritability (2%), insomnia (≤2%), mood swings (≤2%), aggressive behavior (1%), taste disorder (1%), altered sense of smell (≤1%), abnormal dreams, amnesia, anxiety, chills, depression, dizziness, emotional lability, excitement, hostility, malaise, nervousness, outbursts of anger, paresthesia, seizure, sleep apnea, suicidal ideation.

Dermatologic: Acne vulgaris (5%), hyperhidrosis (1%), alopecia, contact dermatitis, diaphoresis, erythema, folliculitis, hair discoloration, pruritus, seborrhea, skin rash, xeroderma.

Endocrine & metabolic: Increased plasma estradiol concentration (3%), weight gain (1%), gynecomastia (≤1%), hot flash (≤1%), change in libido, decreased gonadotropin, fluid retention, hirsutism (increase in pubic hair growth), hypercalcemia, hyperchloremia, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperlipidemia, hypernatremia, hypoglycemia, hypokalemia, inorganic phosphate retention, menstrual disease (including amenorrhea).

Gastrointestinal: Diarrhea (≥3%), gastroesophageal reflux disease, gastrointestinal hemorrhage, gastrointestinal irritation, increased appetite, nausea, vomiting.

Following buccal administration (most common): Dysgeusia, gingival pain, gingival swelling, mouth irritation (including gums), unpleasant taste.

Genitourinary: Prostate specific antigen increase (5% to 11%), prostatitis (≥3%), ejaculatory disorder (1%), prostate induration (1%), spontaneous erections (≤1%), benign prostatic hypertrophy, difficulty in micturition, hematuria, impotence, irritable bladder, mastalgia, oligospermia, priapism, testicular atrophy, urinary tract infection, virilization.

Hepatic: Abnormal hepatic function tests, cholestatic hepatitis, cholestatic jaundice, hepatic insufficiency, hepatic necrosis, hepatocellular neoplasms, increased serum bilirubin, peliosis hepatis.

Hematologic & oncologic: Increased hematocrit (1% to 3%), increased hemoglobin (2%), malignant neoplasm of prostate (1%), anemia, clotting factors suppression, hemorrhage, leukopenia, polycythemia, prostate carcinoma.

Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction (including pulmonary oil microembolism)
Local: Pain at injection site (5%), erythema at injection site (1%), application site reaction (gel, solution), inflammation at injection site
Transdermal system: Application site pruritus (17% to 37%), application site vesicles (including burn-like blisters under system; 6% to 12%), application site erythema (≤7%), local allergic contact dermatitis (4%), application site burning (3%), application site induration (3%), local skin exfoliation (<3%).

Neuromuscular & skeletal: Arthralgia (≥3%), back pain (≥3%), abnormal bone growth (accelerated), hemarthrosis, hyperkinesia, weakness.

Ophthalmic: Increased lacrimation.

Renal: Increased serum creatinine, polyuria.

Respiratory: Bronchitis (≥3%), nasopharyngitis (≥3%), sinusitis (≥3%), upper respiratory tract infection (≥3%), dyspnea.

Drug interactions

Blood Glucose Lowering Agents: Androgens may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Risk C: Monitor therapy.

C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. Risk C: Monitor therapy.

Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens. Risk C: Monitor therapy.

Cyclosporine (Systemic): Androgens may enhance the hepatotoxic effect of Cyclosporine (Systemic). Androgens may increase the serum concentration of Cyclosporine (Systemic). Risk D: Consider therapy modification.

Dehydroepiandrosterone: May enhance the adverse/toxic effect of Testosterone. Risk X: Avoid combination.

Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists. Risk D: Consider therapy modification.

Monitoring parameters

Liver function tests, cholesterol profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy.

Children: Radiographs of left wrist and hand every 6 months (to assess bone maturation).

.Adult females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer.

Dosage forms

Multi dosing vial: 200mg/1 ml  (contains benzyl alcohol).
Anatomic Therapeutic Chemical (ATC) Classification.
Not available.

Mechanism of action

Anabolic steroids sharing some properties. Characterized by its androgenic and anti-glucocorticoid activity.

Active life: 4-6 hours.

Metabolism: Hepatic

Buy steroids online USA.